We thereby demonstrate that CD62L expression is altered in human NAFLD/NASH and that deletion and therapeutic blockade of CD62L in mice prevents development and progression of steatohepatitis by mediating immune cell infiltration and thereby reducing the hepatic oxidative stress environment. Here, SELL is linked to metabolic dysfunction-associated steatotic liver disease.